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Implication for health policy/practice/research/medical education:
The present meta-analysis showed a significant relationship between GA genotype of Gly1057Asp polymorphism and type 
2 diabetes mellitus (OR=0.88; 95% confidence interval, 0.79-0.98), whereas no significant relationship between GG and AA 
genotype with type 2 diabetes mellitus was seen; OR for GG and AA genotypes were 1.10 (95% CI, 0.99 -1.22) and 1.13 (95% CI, 
0.95-1.33), respectively.
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Type 2 diabetes mellitus (T2DM) is a multi-factorial disease in which influenced by several 
genetic and environmental factors. Insulin receptor substrate 2 (IRS 2) is the main mediator 
of insulin in the liver which controls insulin sensitivity. Gly1057Asp polymorphism is one 
of the candidates to increase risk of T2DM. The present study is an attempt to study the 
relationship of Gly1057Asp polymorphism of IRS-2 and T2DM by a meta-analysis. A systemic 
search was conducted in English and Persian databases such as Scopus, PubMed, Google 
Scholar, SID, and other academic databases for studies that have investigated the relationship 
of Gly1057Asp polymorphism of IRS-2 and T2DM. This association was determined using 
odds ratios (ORs) with a confidence interval of 95% (CIs). Heterogeneity of the studies was 
examined by I2 index. Funnel plots and Egger tests were used to determine bias or publication 
bias. The collected data was analyzed in STATA through meta-analysis. Nine articles were 
selected as eligible for further analysis, which represented 3,196 patients with T2DM and 3409 
controls subjects without T2DM. The present meta-analysis showed a significant relationship 
between GA genotype of Gly1057Asp polymorphism and T2DM (OR=0.88; 95% confidence 
interval, 0.79-0.98), whereas no significant relationship between GG and AA genotype with 
T2DM was seen; OR for GG and AA genotypes were 1.10 (95% CI, 0.99 -1.22) and 1.13 (95% 
CI, 0.95- 1.33), respectively. The results of our study show that genotype GA of Gly1057Asp 
polymorphism of IRS-2 gene plays a protective role and may decrease the risk of T2DM, 
whereas GG and AA genotypes are considered as a risk factor and related to development of 
T2DM to some extents. 
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Introduction
Type 2 diabetes mellitus (T2DM) is the most common 
metabolic disorder which manifests a heterogeneous 
group of metabolic diseases. Glucose intolerance is the 
common feature of T2DM, and resulting from by at least 
two pathophysiological defects: impaired insulin signaling 
and failure of pancreatic β cells to compensate for poor 
insulin action through an appropriate increase of insulin 
secretion (1,2). It has been shown that simultaneous 
inheritance of genetic variants at multiple loci, and their 
interaction with environmental factors may contribute to 
the development of type 2 diabetes (3).
Recent studies speculate that the genetic variants of 
different molecules involved in intracellular signaling of 
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insulin receptors in both liver and pancreatic beta cells, 
which play a part in underlying pathogenesis of the type 2 
diabetes (4,5). The insulin receptor substrate-2 (IRS-2) is 
one of these molecules and is one of the major substrates of 
the insulin receptor. Given to its crucial role in the insulin 
signaling system and in development and/or survival of 
pancreatic beta cell, it may be an attractive candidate in 
the pathogenesis of type 2 diabetes (6). It has been shown 
that IRS-2 protein as a key mediator in insulin signaling 
plays a central role in insulin-dependent cellular functions 
such as growth, survival, and metabolism (7).
As well-known, an intracellular signaling cascade begins 
with the binding of insulin to the extracellular α-subunit 
of the insulin receptor could lead to the different biological 
effects in multiple tissues (8,9). One of the most important 
effects of insulin is to stimulate glucose transport. Upon 
insulin stimulation, glucose transporter 4 translocates 
to the plasma membrane, allowing glucose uptake into 
the cell (10). It has been shown that, the insulin receptor 
substrates and phosphatidylinositol 3-kinase (PI3K) are 
two major mediators regulating insulin dependent glucose 
transport, however, there may be other pathways involved 
in glucose uptake (11,12). Additionally, there are evidences 
that show regulatory genes of the proximal insulin 
signaling pathway may contribute to insulin resistance 
and could be potential candidates in pathogenesis of type 
2 diabetes (13). Phosphorylated IRSs (insulin receptor 
substrate proteins) act as docking proteins between the 
insulin receptor and a complex network of intracellular 
signaling molecules containing Src homology 2 domains, 
including the p85 subunit of phosphatidylinositol (PI) 
3-kinase (7). Under normal circumstances, once insulin 
binds to its cell surface receptors, the intracellular tyrosine 
residues of receptor undergo auto-phosphorylation by 
its self-tyrosine kinase activity and then the downstream 
cascade of events is started (10-12). In subsequent, other 
downstream regulatory proteins such as insulin receptor 
substrate family of IRS-1/2/3/4 and Shc phosphorylated 
by turn with tyrosine kinase activity of insulin receptor 
(14). Moreover, insulin messaging may be regulated with 
activity of phosphotyrosine protein phosphatase (PTPase), 
via the dephosphorylation of insulin receptor substrate 1/2 
and Shc (15). The Shc family of adaptor proteins is a group 
of proteins that lacks intrinsic enzymatic activity. IRS1 
and IRS2 are known as adapter proteins for SH2-domain 
containing Src messenger proteins including Nck-SHP2-
Grb-2-sos complex and lipid kinase regulatory subunit 
which is known as PI-3-kinase (16). Binding of the IRS 
to p85, as a regulatory subunit of PI-3-kinase, activate 
the PI-3-kinase-PKB/AKT pathway that is necessary for 
fulfillment of the insulin action on glucose transport and 
construction of glycogen in the liver (17).
Up to now, several SNPs have been identified and 
reported in the IRS-2 gene in humans (18). One of the 
most frequent of these is a variant causing a Gly1057Asp 
substitution. In addition, four other SNPs which rarely 
occur have been identified result in variants causing an 
Ala157Thr substitution, a Leu647Val substitution, a 
Gly879Ser substitution, along with an AAC insertion 
(Asn) in the Asn repeat sequence centered on codons 
of 29–36 (7). Among those variants, the Gly1057Asp 
substitution has been found to be more associated with 
increased risk for the T2DM in some populations (16).
IRS2G1057D as a replacement of G(glycine) by D (aspartic 
acid) takes place at site 1057 of insulin receptor substrate-2 
and results from a simple nucleotide substitution or 
polymorphism (SNP) in IRS2 gene (rs1805097) (19). The 
association of this polymorphism with type 2 diabetes has 
been studied in different populations, but the inconsistent 
results have been reported. Some studies reported an 
association between Gly1057Asp polymorphism of IRS-2 
and susceptibility to T2DM, whereas others have reported 
controversial data (20-28). To authenticate these studies 
and as a way of synthesizing their findings, performing 
a meta-analysis study seemed necessary. In the present 
study we aimed to investigate and identify the association 
of these polymorphisms with T2DM by a meta-analysis 
and literature review. 
Search strategy
We searched the PubMed, Scopus, Google Scholar, Web 
of Science, Embase, and the Cochrane Library databases 
to identify any articles published in English on the 
relationship between Gly1057Asp polymorphism of IRS-
2 gene with type 2 diabetes. Searching was done using 
keywords including IRS-2, Type 2 diabetes, Gly1057Asp, 
rs1805097. The Persian equivalent of these terms and all 
probable combinations were used to search in Persian 
databases (i.e., IranMedex, Magiran, SID, and Iran doc). 
The advanced search was performed with a combination 
of words or phrases using Boolean operators (‘AND’, ‘OR’, 
‘NOT’). The references list of all related reviews and main 
articles were examined to identify any further publications 
that were not retrieved in the online search.
Inclusion and exclusion criteria
In the next stage, the obtained studies of searching process 
were tested precisely to be included in the study. All case 
studies and meta-analysis studies on IRS-2 and T2DM 
were reviewed. Articles that had determined Gly1057Asp 
polymorphism of IRS-2 gene in type 2 diabetes patients 
and control subjects without T2DM were considered 
eligible and included for further analysis. Some studies 
were out of the realm of the current study and thus were 
excluded, if they perform on non-human creatures (i.e. 
animal studies), if they were meta-analyses or systematic 
reviews, if they presented insufficient data, and those were 
published in other than English and Persian languages.
Data extraction
The fol lowing data and information were extracted 
from the studies; the name of first writer, study location, 
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publication year, and sample size and also the number of 
genotypes GG, GA, AA of Gly1057Asp polymorphism 
in T2DM patients and control subjects without T2DM. 
In cases which needed more information, the articles’ 
writers were contacted for supplementary data or further 
elucidation.  All these procedures were conducted by two 
authors independently and any disagreement was resolved 
by consensus. The data were entered into data collection 
forms and entered into Microsoft Excel.
Statistical analysis
The odds ratio (OR) with a confidence interval of 95% 
was computed as the measuring standard of the relation 
between Gly1057Asp polymorphism of IRS-2 gene with 
type 2 diabetes for both individual trials and pooled 
estimates. To obtain OR and combined ORs, the Peto odds 
ratio method was utilized. Heterogeneity of the articles 
was examined using Q and I2 Cochran statistics. While 
the results of studies were heterogeneous, random effects 
models were used in the meta-analysis. Additionally, 
when there was no heterogeneity for the outcome, the 
fix effects model was applied to pool analysis and verses. 
The findings are described in forest plots (the point 
estimations and their 95% CI). Meta-regression was used 
to survey the relationship between year of study and OR 
value.  Funnel plots and Egger test were used to examine 
publication bias. Values of P < 0.05 were considered as 
valid for heterogeneity tests. The data was analyzed with 
software R (version 2.15.1) and STATA (version 11.2). 
Results
In the search process, 27 potential articles were identified; 
6 of them were review and repetitive studies which were 
removed from analysis, thus abstracts of 21 articles were 
remained. In the next step, 10 articles were excluded based 
on unrelated titles and abstracts. We also removed two 
studies from the list after screening of full text. Eventually, 
9 articles were selected for the final analysis (Figure 1).
All these studies were case-control studies and published 
from 1999 to 2012. Studies were conducted in different 
countries; two in Italy (24,27) and one for each in Finland 
(23), Iran (20), India (21), Germany (26), Netherlands (25), 
Japan (22), Denmark and Sweden (28). The total sample 
size was 6605 participants containing 3196 T2DM patients 
and 3409 control subjects without T2DM; including 1573 
cases and 1620 controls with GG genotype, 1275 cases 
and 1,451 controls with genotype GA, and 348 cases and 
338 controls with AA genotype. The characteristics of the 
eligible studies are listed in Table 1. 
In the current meta-analysis, OR for genotype GG 
based on fixed effects model was 1.10 (confidence 
interval of 95% from 0.99 to 1.22). We found no evidence 
of heterogeneity (I2 = 15.6%, P = 0.304; Figure 2). This 
shows that this polymorphism is related to development 
of T2DM to some extents and it is considered as a risk 
factor (P = 0.05). 
Figure 3 presents the Begg’s funnel plot related to 
GG genotype and T2DM for detecting publication 
bias; According to this figure, the effect of bias was not 
significant (P = 0.504). Additionally, Egger’s regression 
asymmetry test revealed no evidence of publication bias 
(P = 0.156).
The result indicated that there was a significant 
relationship between GA genotype and T2DM. The odds 
ratio for genotype GA based on fixed effects model was 
0.88 (CI: 95%, 0.79-0.98; Figure 4). Taking into account 
that, the confidence interval does not include 1 for total 
OR, it can be said that the gene plays a protective role 
Figure 1. Flowchart of selecting relevant studies for meta-analysis.
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and having this polymorphism may decrease the risk of 
T2DM. Given I2 index, the results of different studies are 
homogeneous (I2 = 46.6%, P = 0.049; Figure 4). Based on 
Figure 5, there is a bias in publication. 
Our meta-analysis based on fixed effects model found 
no significant relationship between genotype AA and 
T2DM; OR was 1.13 (CI: 95%; 0.96-1.33). However, the 
genotype still is considered as a risk factor of the disease. 
That is, OR of T2DM in individuals with this genotype 
is 1.13 times of individuals without this genotype. The 
difference, however, is not significant. 
The included studies showed limited evidence of 
heterogeneity (I2 = 1.2%, P = 0.427; Figure 6).
Funnel plot and Egger tests showed no evidence of 
publication bias (P = 0.541 for Egger; P = 0.858 for Begg; 
Figure 7).
Discussion 
The candidate gene approach is a common approach to 
define contribution of genetic variants as a risk factor in 
susceptibility to many diseases such as T2DM (29). In 
regard to T2DM, this approach tries to find a relationship 
between T2DM and sequence of the variants (determined 
based on physiological performance) within or in vicinity 
of the candidate gene. In order to find importance of 
different variants with other close variants, their frequency 
in T2DM patients and controls are compared (27). Many 
Table 1. Study characteristics
First Author/
References
Published 
Year Country
Total sample
(case)
Total sample
(control)
OR (95% CI)
GG GA AA
Haghani K (20) 2012 Iran 336 341 0.59 1.56 1.70
Bodhini D (21) 2007 India 1018 1193 1.20 0.74 1.43
Okazawa K (22) 2005 Japan 123 260 0.99 0.99 1.03
Laukkanen  O (23) 2004 Finland 248 242 1.01 0.99 1.01
D’Alfonso R (24) 2003 Italy 240 186 1.16 0.94 0.82
Leen M (25) 2002 Netherlands 94 64 0.64 1.37 1.44
Fritsche A (26) 2001 Germany 77 318 0.79 1.33 0.85
Mammarella S (27) 2000 Italy 193 206 1.23 0.91 0.73
Almind K (28) 1999 Denmark and Sweden 228 363 1.37 0.67 1.21
Almind K (28) 1999 Denmark and Sweden 639 236 0.90 1.18 0.87
Figure 2. Relationship between Gly1057Asp polymorphism of IRS-2 gene (GG genotype) and susceptibility to diabetes type II based on fixed effects model. 
Midpoint of each segment is the estimate of prevalence and segment lengths shows the 95% confidence intervals for each study. The diamond mark shows 
the prevalence in the whole country for all studies.
Figure 3. Begg’s funnel plot for publication bias (GG genotype).
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studies suggest that among several variants of IRS-2 gene, 
Gly1057Asp polymorphism is an important candidate for 
development of T2DM (30-32). The present meta-analysis 
from nine conducted articles did not show a significant 
relationship between Gly1057Asp polymorphisms and 
increased risk of T2DM.
There are several studies have been conducted in 
different populations to find the relationship between 
Gly1057Asp variant of IRS-2 and T2DM. However, the 
findings are controversial regarding the effect of these 
variant on OR of T2DM and relevant metabolic traits 
(20-28,33). Okazawa et al reported a strong relationship 
between G1057D variant of IRS-2 and susceptibility 
to T2DM (22). Additionally, Stefan et al reported that 
carriers of DD genotype demonstrated low sensitivity to 
insulin in the liver and pancreatic beta cells (30). However, 
in contrast, Almind et al reported no relationship between 
G1257D variant of IRS-2 and T2DM predisposition on 
white populations (28). Interestingly, D’Alfonso et al 
showed that the frequency of Gly1057Asp variant of IRS-2 
Figure 4. Relationship between Gly1057Asp polymorphism of IRS-2 gene (GA genotype) and susceptibility to diabetes type II based on fixed effects model. 
Midpoint of each segment is the estimate of prevalence and segment lengths shows the 95% confidence intervals for each study. The diamond mark shows 
the prevalence in the whole country for all studies.
Figure 5. Begg’s funnel plot for publication bias (GA genotype).
was not related to common form of T2DM. Their results, 
apparently, indicated that the subjected variant does not 
influence all clinical and biochemical metrics in T2DM 
patients and non-T2DM individuals (24). Furthermore, 
D’ Alfonso et al argued that Gly1057Asp variant of IRS-
2 is related to low and high prevalence of T2DM in 
normal and overweight individuals (24). In this regard 
we found a significant relationship between GA genotype 
of Gly1057Asp polymorphism and T2DM, whereas no 
significant relationship between GG and AA genotype 
with T2DM was observed. These results are inconsistent 
with D’Alfonso et al and other reports in Danish, German, 
Dutch, Finn and Chinese populations (25,26,28,34,35), 
which somehow are consistent with the result of study 
in the Italian population (27). Another study conducted 
in Denmark to find the frequency of this polymorphism, 
however, the results showed no relationship with 
susceptibility to T2DM (34). The result of study in middle 
age non-diabetic Danish population with D1057 allele 
showed decreased levels of serum insulin and C-peptide 
in oral glucose tolerance test (OGTT) (28). Moreover, 
the findings of a study in German population showed 
no relationship between the polymorphism and insulin 
sensitivity or insulin secretion levels, while the results 
showed the influence of the polymorphism in the same 
population on overweight and performance of the 
pancreatic beta cells (30). In line with these findings, the 
result of studies in Italy and Japan showed no relationship 
between this polymorphism and susceptibility to T2DM 
(24-27,36,37). Thereby, it appears that a considerable 
difference between the relationship of Gly1057Asp variant 
of IRS-2 and type 2 diabetes exists. 
The underlying molecular mechanisms of how G1057D 
causes non-protective effect on the improvement insulin 
performance are still not clear. It is assumed that a charged 
amino acid (D) was introduced by D1057 variant in place 
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of natural type of (G) in the domain of IRS-2 molecule 
between two putative tyrosine phosphorylation sites (1042 
and 1072 positions), may cause changes in downstream 
signals through IRS-2 (27).
The results of our study show that genotype GG and AA 
genotypes of Gly1057Asp polymorphism of IRS-2 gene 
are related to development of T2DM to some extents. 
Most of the reviewed studies in this meta-analysis showed 
that frequency of DD genotype among patients with 
T2DM was higher than that of non-diabetic individuals 
(20-23,25,28). These and other studies have been proven, 
the presence of a direct relationship between D allele of 
Gly1057Asp IRS-2 and T2DM (30,32,39,40). Nevertheless, 
others reported that DD genotype was lower in T2DM 
patients than the compared group (24,26,27) while, some 
of them have failed to show the relationship between the 
subjected polymorphism and susceptibility to T2DM (33-
35,38), which are not consistent with our results. Bodhini 
et al showed that D1057D genotype of IRS-2 among 
Figure 6. Relationship between Gly1057Asp polymorphism of IRS-2 gene (AA genotype) and susceptibility to diabetes type II based on fixed effects model. 
Midpoint of each segment is the estimate of prevalence and segment lengths shows the 95% confidence intervals for each study. The diamond mark shows 
the prevalence in the whole country for all studies.
Figure 7. Begg’s funnel plot for publication bias (AA genotype).
Asian-Indians interacts with susceptible to diabetes and 
obesity. Their survey revealed the DD genotype role in 
susceptibility to T2DM which appears only in the case of 
obesity and indicated that DD genotype could be used as 
a genetic indicator for obese individuals who have more 
susceptibility to T2DM (21). Other researcher argued that 
D1057 allele is negatively and positively related to T2DM 
among non-obese and obese patients, respectively. This 
means that D1057 allele could increase the risk of diabetes 
among obese persons (27). We combined the obtained 
results from studies conducted in this regard and observed 
a mild association between D1057D genotype of IRS-2 and 
increased risk of T2DM. Hence, it could be considered AA 
genotypes of Gly1057Asp polymorphism of IRS-2 gene as 
a risk factor for the development of T2DM. 
Our survey also showed that genotype GA of Gly1057Asp 
polymorphism of IRS-2 gene plays a protective role 
and may decrease the risk of T2DM. Among included 
studies, six of them found that frequency of genotype 
GA of Gly1057Asp polymorphism among non-diabetic 
individuals was higher than that of patients with 
T2DM (21-24,27,28). Whereas, others reported that, 
this genotype was higher in T2DM patients than non-
diabetic group (20,25,26). Some studies indicated a direct 
relationship between genotype GA of Gly1057Asp IRS-
2 and decreased risk of T2DM (21,28). These findings 
suggest that the genotype might act as a protective factor 
against T2DM, which are consistent with our results.
The studies among Japanese and Italian population 
indicated that IRS-2 gene may act as a modifier of insulin 
sensitivity among T2DM patients (22,27). D’Alfonso et al 
examined the effect of IRS-2 variant on cellular function 
in fibroblasts from carriers of different types of genotypes. 
They found that Gly1057Asp polymorphism does not 
change expression level tyrosine phosphorylation of IRS-
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2 in response to insulin, it also caused no disturbance 
in capability of IRS-2 to bind to p85, the regulatory 
unit of PI 3-kinase (24). These results are in support of 
the idea that Gly1057Asp variant does not influence 
IRS-2 performance. Thereby, it could be concluded that 
Gly1057Asp variant of IRS-2 does not influence insulin 
secretion levels and insulin sensitivity or does not disturb 
the performance of IRS-2. Furthermore, Fritsche et al 
found no proof for the role of Gly1057Asp polymorphism 
of IRS-2 on functional biodiversity of the beta cells. Their 
results indicated that capacity of beta cells is not affected by 
the presence of this polymorphism. They concluded that 
Gly1057Asp in IRS-2 does not play an independent role in 
β-cell dysfunction (26). These results are very inconsistent 
with the idea that IRS-2 polymorphism plays a key role 
in pathogens of T2DM (24,26). Similarly, we found no 
relationship between Gly1057Asp polymorphism of IRS-2 
gene and development of T2DM. Since the Gly1057Asp 
polymorphism is the most common genetic variant of 
IRS-2 in human, it does not seem to be probable that this 
protein acts as a protector of the genetic variant effective 
on the major way of reduction of insulin secretion and 
development of T2DM (26). 
Conclusion
The present meta-analysis from nine published articles 
does not find a significant relationship between 
Gly1057Asp polymorphisms and the increased risk 
of T2DM. Our study also showed that genotype GA 
of Gly1057Asp polymorphism of IRS-2 may decrease 
the risk of T2DM, whereas homozygous genotypes for 
the Gly1057Asp variant (GG and AA genotypes) were 
partly associated with development of T2DM. We found 
a considerable difference between the frequencies of 
Gly1057Asp polymorphisms on IRS-2 gene in different 
studies. Geographical differences may partially explain 
variations in distribution of the genotypes. In addition, 
differences in body mass index and age of the subjects 
also explain different results to some extents. Moreover, 
differences in the methods used to assess T2DM may 
account for the disparity. It is notable in summary that 
small number of studies in this field hints necessity of 
further studies in different populations to examine effects 
of Gly1057Asp polymorphism on IRS-2 gene and to 
clarify its relationship with T2DM.
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